Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics announced that the independent Data Monitoring Committee for its ELEVATE-45-201 study has recommended escalating the dose for Cohort 2 to 10 mg/kg. This decision follows a review of safety and pharmacokinetic data from eight participants in Cohort 1, who were treated at 5 mg/kg.
Key figures
- Drug Name
- ENTR-601-45
- Phase Of Trial
- Phase 1/2
- Max dose
- 15 mg/kg
- Cohort1 dose
- 5 mg/kg
- Cohort2 dose
- 10 mg/kg
- Dosing frequency
- once every six weeks
- Total participants
- 24
- Cohort1 participants
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.